Department of Neurology, Peritz and Chantal Scheinberg Cerebrovascular Research Laboratory, Hadassah Ein Kerem, Jerusalem, Israel.
CNS Neurol Disord Drug Targets. 2012 Nov 1;11(7):921-5. doi: 10.2174/1871527311201070921.
Stroke is a leading cause of mortality and chronic disability. Therapies aimed at reducing stroke related morbidity are currently limited. Therefore it is very important to develop effective treatments that will maximize rehabilitation after stroke. Current efforts in the field of cellular therapy focus on stem cell transplantations. This approach involves biological and ethical complications and therefore, the use of endogenous neural stem cells (eNSC) for repairing damage in various neurological disorders has been suggested. eNSCs reside in specialized vascular niches in defined regions, such as the subventricular zone (SVZ) of the lateral ventricle. These cells have an unlimited potential to create newborn cells. Interrelations between newborn neural and endothelial cells have an important role in eNSC survival, maturation, migration and differentiation and neurogenesis occurs in close spatio-temporal association with vessel growth in these niches. Previous studies have shown that application of external factors can boost long-term endogenous repair mechanisms in the cerebral cortex. Activated platelets and their microparticles contain a variety of growth and trophic factors essential to angiogenesis and neurogenesis and may therefore serve as novel therapeutic agents for brain injury. Specifically, factors from platelets and their microparticles may promote neurogenesis by stimulating eNSC proliferation, migration and differentiation, and by stimulating niche angiogenesis and the release of neurogenic signals from endothelial cells and astrocytes. In this review we will show that combined augmentation of angiogenesis, neurogenesis and neuroprotection using platelets and their microparticles is feasible and results in improved functional gain after stroke.
中风是导致死亡和慢性残疾的主要原因。目前旨在降低中风相关发病率的治疗方法有限。因此,开发能在中风后最大限度促进康复的有效治疗方法非常重要。目前细胞治疗领域的努力集中在干细胞移植上。这种方法涉及到生物学和伦理方面的复杂性,因此,人们建议使用内源性神经干细胞(eNSC)来修复各种神经疾病的损伤。eNSC 存在于特定的血管壁龛中,位于脑室的侧脑室下区(SVZ)等特定区域。这些细胞具有无限的产生新细胞的潜力。新生神经细胞和内皮细胞之间的相互关系对 eNSC 的存活、成熟、迁移和分化起着重要作用,并且在这些壁龛中,神经发生与血管生长密切相关。以前的研究表明,应用外部因素可以促进大脑皮层中内源性修复机制的长期存在。活化的血小板及其微颗粒包含了促进血管生成和神经发生所必需的各种生长和营养因子,因此可以作为治疗脑损伤的新型治疗剂。具体来说,血小板及其微颗粒中的因子可以通过刺激 eNSC 的增殖、迁移和分化,以及刺激壁龛血管生成和内皮细胞和星形胶质细胞释放神经发生信号,从而促进神经发生。在这篇综述中,我们将表明,使用血小板及其微颗粒联合增强血管生成、神经发生和神经保护是可行的,并能在中风后提高功能恢复。